Mestranol-Induced Reversible Lysosomal Stress in Zebrafish Microglia

Study Background and Research Question

Microglia play a pivotal role in central nervous system (CNS) health, acting as resident immune cells responsible for the removal of apoptotic neurons and cellular debris via phagocytosis and lysosomal degradation. Efficient lysosomal function underpins their homeostatic and neuroprotective activities, and impaired lysosomal pathways are increasingly implicated in neurodevelopmental and neurodegenerative disorders. While genetic models of lysosomal storage diseases (LSDs) have clarified many pathogenic mechanisms, the potential for environmental or pharmacological agents to induce a similar lysosomal dysfunction in vivo—and whether such a state is reversible—remains largely unexplored. The reference study (Zhu et al., 2026) addresses this gap by investigating how mestranol, a synthetic estrogenic compound, affects microglial lysosomal homeostasis in zebrafish larvae.

Key Innovation from the Reference Study

The central innovation of this research lies in establishing that mestranol exposure can induce a lysosomal storage–like state in microglia within a live vertebrate model and, importantly, that this state is reversible upon withdrawal of the compound. This pharmacologically induced phenotype recapitulates several features of classical LSDs—most notably, microglial hypertrophy and impaired lysosomal cargo digestion—without relying on genetic mutations. The study also reveals coordinated downregulation of lysosomal and immune gene networks, suggesting that estrogenic environmental toxicants can acutely suppress microglial function through transcriptional reprogramming. This model thus provides new tools for dissecting environmental impacts on microglia and for screening potential neuroimmunotoxicants.

Methods and Experimental Design Insights

The research employed zebrafish larvae as an in vivo imaging platform, leveraging their optical transparency and conserved innate immune system. Key experimental steps included:

• Exposure of zebrafish larvae to mestranol at defined developmental stages.
• Quantification of microglial morphology and lysosomal status using vital dye (neutral red) uptake and live microscopy.
• Assessment of microglial number and phagocytic function by tracking uptake and digestion of apoptotic neurons and fluorescently labeled bacterial particles.
• Flow cytometric sorting of macrophage/microglia populations for transcriptomic profiling to evaluate changes in lysosomal, phagosomal, and immune gene expression.
• Overexpression of TFEC, a MIT/TFE family transcription factor, to test partial rescue of mestranol-induced phenotypes.
• Drug washout experiments to determine reversibility of the induced lysosomal phenotype.

Protocol Parameters

• Mestranol exposure: Applied to zebrafish larvae at specific developmental windows; concentrations and durations optimized for in vivo imaging and toxicity avoidance.
• Neutral red staining: Used for live visualization of lysosomal compartments; performed after mestranol treatment to assess lysosomal function.
• Microglial phagocytosis assays: Implementation of apoptotic neuron labeling and bacterial particle uptake, followed by imaging and quantification.
• Gene expression analysis: Flow-sorted microglia/macrophage populations subjected to RNA sequencing for differential expression profiling.
• TFEC overexpression: Introduced via genetic manipulation to probe transcriptional rescue mechanisms.
• Reversibility assessment: Mestranol withdrawal and subsequent monitoring of microglial phenotype recovery.

Core Findings and Why They Matter

Key findings from the reference study include:

• Induction of lysosomal storage–like phenotype: Mestranol exposure led to pronounced microglial hypertrophy and a marked reduction in neutral red staining, consistent with lysosomal dysfunction.
• Preserved phagocytic uptake, impaired cargo digestion: Despite normal uptake of apoptotic neurons and bacterial particles, mestranol-treated microglia accumulated undigested cargo, indicating a failure of intracellular digestion rather than phagocytic entry.
• Expansion and dispersal of acidic vesicles: Acidic lysosomal compartments expanded and dispersed throughout the cytoplasm, but failed to restore degradative efficiency.
• Downregulation of key transcriptional regulators: Transcriptomic analysis revealed coordinated suppression of lysosomal–phagosomal and immune gene networks, affecting MIT/TFE transcription factors (such as TFEB/TFEC) and immune master regulators (SPI1, IRFs, BATF, MAFB, RUNX3).
• Partial rescue by TFEC overexpression: Restoration of TFEC expression partially reversed hypertrophy and lysosomal defects, though not fully, implicating additional, TFEC-independent mechanisms.
• Reversibility of the induced state: Upon withdrawal of mestranol, microglial morphology and lysosomal function normalized, indicating that the induced phenotype is not permanent.

These results are significant for several reasons. First, they provide a live, dynamically regulatable model for studying how environmental estrogens disrupt microglial physiology. Second, they demonstrate that microglial lysosomal dysfunction can arise through non-genetic, reversible mechanisms, broadening the scope of environmental neurotoxicology research. Third, the transcriptional suppression of lysosomal and immune pathways highlights a mechanism by which environmental estrogens could exacerbate vulnerability to neurodegeneration or infection.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on apoptosis detection and lysosomal stress in microglia research. For instance, "Annexin V-Cy5: Advancing Apoptosis Detection in Neuroimmunology" links the mechanistic insights from lysosomal stress models to practical apoptosis assay strategies, underscoring the translational potential for neurodegenerative and toxicological studies. Similarly, "Annexin V-Cy5 Apoptosis Kit: Decoding Microglial Apoptosis and Lysosomal Stress" offers advanced workflow guidance for integrating apoptosis detection with lysosomal dysfunction analysis. These articles highlight the value of robust, fluorescence-based apoptosis assays—such as those enabled by Annexin V-Cy5 labeling—in dissecting the interplay between cell death and lysosomal impairment in live models. The current reference expands on these themes by providing a direct in vivo demonstration of how environmental factors can induce lysosomal stress independently of apoptotic cell death, suggesting new avenues for protocol refinement and multi-parametric analysis in microglia research.

Limitations and Transferability

While the zebrafish model offers unique advantages for live imaging and genetic manipulation, extrapolating findings to mammalian systems requires caution. The dose and duration of mestranol exposure were optimized for zebrafish larvae, and equivalent effects in adult vertebrates or humans remain to be established. Additionally, the partial rescue by TFEC overexpression indicates that the regulatory networks involved are complex and not fully elucidated. The study does not address long-term consequences of transient lysosomal stress or potential cumulative effects with repeated environmental exposures. Finally, although apoptosis was monitored and found unaffected, the interplay between lysosomal dysfunction and apoptotic pathways warrants further exploration using highly sensitive apoptosis detection methods.

Research Support Resources

Researchers aiming to model lysosomal stress or assess microglial apoptosis in environmental toxicology and neurodegenerative disease contexts can benefit from advanced apoptosis detection tools. The Annexin V-Cy5 Apoptosis Kit (SKU K2005) from APExBIO enables rapid and sensitive quantification of early apoptotic cells in live tissues, supporting both fluorescence microscopy and flow cytometry-based workflows. For further protocol optimization and context-specific guidance, refer to internal resources such as "Annexin V-Cy5: Advancing Apoptosis Detection in Neuroimmunology" and "Annexin V-Cy5 Apoptosis Kit: Decoding Microglial Apoptosis and Lysosomal Stress".